Latest Research And Development News

Firebird Metals has secured a key patent for its energy-efficient kiln and announced plans for an Australian Demonstration Plant to commercialise its battery materials technology.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

International Graphite Limited has finalized the purchase of industrial land in Collie, Western Australia, setting the stage for Australia’s first commercial graphite micronising facility amid rising global demand.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Straker Ltd reports a solid first half of FY26 with positive EBITDA and a renewed IBM partnership, despite a 15% revenue decline amid challenging market conditions.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.

Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.

Aroa Biosurgery has reported a strong first half for FY26, with 14% revenue growth driven by its Myriad product line and a return to positive EBITDA. The company also secured relief from ASX quarterly reporting requirements, signaling improved financial stability.

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.